Surgery Partners Inc (SGRY) Shares Soar Above 1-Year High

Surgery Partners Inc (NASDAQ: SGRY) has seen a rise in its stock price by 9.49 in relation to its previous close of 25.60. However, the company has experienced a 12.34% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-05-07 that Surgery Partners (SGRY) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.08 per share a year ago.

Is It Worth Investing in Surgery Partners Inc (NASDAQ: SGRY) Right Now?

Additionally, the 36-month beta value for SGRY is 2.73. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”

The public float for SGRY is 72.99M and currently, short sellers hold a 11.78% ratio of that float. The average trading volume of SGRY on May 07, 2024 was 919.91K shares.

SGRY’s Market Performance

The stock of Surgery Partners Inc (SGRY) has seen a 12.34% increase in the past week, with a 2.49% rise in the past month, and a -13.91% fall in the past quarter. The volatility ratio for the week is 4.59%, and the volatility levels for the past 30 days are at 4.03% for SGRY. The simple moving average for the last 20 days is 11.67% for SGRY stock, with a simple moving average of -8.25% for the last 200 days.

Analysts’ Opinion of SGRY

Many brokerage firms have already submitted their reports for SGRY stocks, with Barclays repeating the rating for SGRY by listing it as a “Equal Weight.” The predicted price for SGRY in the upcoming period, according to Barclays is $35 based on the research report published on March 06, 2024 of the current year 2024.

TD Cowen, on the other hand, stated in their research note that they expect to see SGRY reach a price target of $35, previously predicting the price at $39. The rating they have provided for SGRY stocks is “Outperform” according to the report published on November 14th, 2023.

BofA Securities gave a rating of “Buy” to SGRY, setting the target price at $45 in the report published on June 02nd of the previous year.

SGRY Trading at 1.76% from the 50-Day Moving Average

After a stumble in the market that brought SGRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.79% of loss for the given period.

Volatility was left at 4.03%, however, over the last 30 days, the volatility rate increased by 4.59%, as shares surge +1.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.30% lower at present.

During the last 5 trading sessions, SGRY rose by +12.20%, which changed the moving average for the period of 200-days by -30.13% in comparison to the 20-day moving average, which settled at $25.12. In addition, Surgery Partners Inc saw -12.38% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at SGRY starting from Doherty David T, who sale 721 shares at the price of $28.59 back on Mar 14 ’24. After this action, Doherty David T now owns 95,719 shares of Surgery Partners Inc, valued at $20,613 using the latest closing price.

Evans Jason Eric, the Chief Executive Officer of Surgery Partners Inc, sale 4,840 shares at $29.71 during a trade that took place back on Mar 13 ’24, which means that Evans Jason Eric is holding 459,670 shares at $143,796 based on the most recent closing price.

Stock Fundamentals for SGRY

Current profitability levels for the company are sitting at:

  • 0.14 for the present operating margin
  • 0.22 for the gross margin

The net margin for Surgery Partners Inc stands at 0.02. The total capital return value is set at 0.06. Equity return is now at value -0.60, with -0.17 for asset returns.

Based on Surgery Partners Inc (SGRY), the company’s capital structure generated 0.52 points at debt to capital in total, while cash flow to debt ratio is standing at 0.14. The debt to equity ratio resting at 1.08. The interest coverage ratio of the stock is 3.76.

Currently, EBITDA for the company is 526.6 million with net debt to EBITDA at 6.87. When we switch over and look at the enterprise to sales, we see a ratio of 2.34. The receivables turnover for the company is 5.34for trailing twelve months and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.71.

Conclusion

In conclusion, Surgery Partners Inc (SGRY) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts